Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Gains from Sales and Divestitures (2016)

Historic Gains from Sales and Divestitures for Agios Pharmaceuticals (AGIO) over the last 5 years, with Q4 2016 value amounting to $7500.0.

  • Agios Pharmaceuticals' Gains from Sales and Divestitures fell 1199.25% to $7500.0 in Q4 2016 from the same period last year, while for Dec 2016 it was $7500.0, marking a year-over-year decrease of 1199.25%. This contributed to the annual value of $7500.0 for FY2016, which is 1199.25% down from last year.
  • Agios Pharmaceuticals' Gains from Sales and Divestitures amounted to $7500.0 in Q4 2016, which was down 1199.25% from $7500.0 recorded in Q3 2016.
  • Agios Pharmaceuticals' Gains from Sales and Divestitures' 5-year high stood at $183713.0 during Q4 2012, with a 5-year trough of $2841.0 in Q1 2015.
  • In the last 5 years, Agios Pharmaceuticals' Gains from Sales and Divestitures had a median value of $9091.0 in 2014 and averaged $42003.6.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Gains from Sales and Divestitures tumbled by 9055.12% in 2014, and later surged by 3201.9% in 2016.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Gains from Sales and Divestitures stood at $183713.0 in 2012, then dropped by 25.56% to $136758.0 in 2013, then plummeted by 89.2% to $14773.0 in 2014, then tumbled by 42.31% to $8522.0 in 2015, then dropped by 11.99% to $7500.0 in 2016.
  • Its Gains from Sales and Divestitures was $7500.0 in Q4 2016, compared to $7500.0 in Q3 2016 and $7500.0 in Q2 2016.